Cite
HARVARD Citation
Davis, E. et al. (2022). First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors. Journal for immunotherapy of cancer. 10 (10), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Davis, E. et al. (2022). First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors. Journal for immunotherapy of cancer. 10 (10), p. . [Online].